This study is evaluating the experimental drug selgantolimod (SLGN) for patients with Chronic Hepatitis B (CHB) to try to prevent progression and reverse disease. 

Experimental means that SLGN has not yet been approved by the U.S. Food and Drug Administration (FDA). 

This study will assess how safe and tolerated treatment is. It will also assess the amount of hepatitis B surface antigen (HBsAg) in a person's blood during and after 24 weeks of treatment. HBsAg is an important test that shows active infection with hepatitis B virus (HBV) and helps in the prediction of the clinical outcome and management of HBV without HIV.

This study will have two groups: those who will receive SLGN and those who will receive placebo. Participants will be randomized 3:1 to the active treatment arm. This means that there is a 75% chance of getting assigned to receive SLGN, and a 25% chance of receiving placebo. Participants will take the medication once weekly by mouth for 24 weeks.

This study intends to establish the safety profile, tolerability, and effect on amount of HBsAg in a participant’s blood when given over 24 weeks in persons living with Human Immunodeficiency Virus (HIV) and CHB.